Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication Sort descending | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
GUANABENZ ACETATE | IMPURITIES/Limit of 2,6-Dichlorobenzaldehyde/Chromatographic system | USP42–NF37 | 2129 | 31-May-2019 | 1-Jun-2019 | NA | NA | In Column: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm; |
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 26-Feb-2021 | 1-Mar-2021 | NA | NA | In USP Amlodipine Related Compound A RS: Change 522.93 to: 522.94 |
DESFLURANE | CHEMICAL INFORMATION | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether to: (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane. |
ZIPRASIDONE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 4699 | 30-Jul-2021 | 1-Aug-2021 | NA | NA | In USP Ziprasidone Related Compound F RS: Change 2-(2-Amino-5-{2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid. C21H23ClN4O2S 430.95 to: Sodium 2-(2-… Read More |
RALTEGRAVIR TABLETS | DEFINITION | USP43–NF38 | 3834 | 24-Apr-2020 | 1-May-2020 | NA | NA | Change (C20H20FN6O5) to: (C20H21FN6O5) |
ONDANSETRON ORALLY DISINTEGRATING TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. C16H20N2O · HCl 292.80 to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,… Read More |
FUROSEMIDE TABLETS | Limit of furosemide related compound B | USP43–NF38 | 2056 | 31-Jul-2020 | 1-Aug-2020 | NA | NA | Change Mobile phase, Diluting solution, System suitability solution, and Chromatographic system—Prepare as directed in the test for Related compounds under Furosemide. to: Mobile phase—Prepare a… Read More |
AMMONIUM GLYCYRRHIZATE | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change 840.08 to: 839.97 |
ROCURONIUM BROMIDE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | In footnote b of Table 1: Change 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstan-3α,17β-diol. to: 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstane-3α,17β-diol. |
PSEUDOEPHEDRINE HYDROCHLORIDE TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change Uniformity of Dosage Units 〈905〉 Procedure for content uniformity to: Uniformity of Dosage Units 〈905〉: Meets the requirements Procedure for content uniformity, chewable tablets only AND In … Read More |
TELMISARTAN TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 27-Oct-2023 | 1-Nov-2023 | NA | NA | In Dissolution 〈711〉/Test 1/Analysis: Change Determine the percentage of telmisartan (C33H30N4O2) dissolved: Result = (AU × CS × V × 100)/(A… Read More |
LEVALBUTEROL INHALATION SOLUTION | IMPURITIES/Limit of S-Albuterol | USP42–NF37 | Online | 26-Apr-2019 | 1-May-2019 | NA | NA | In Mobile phase: Change ▲Acetonitrile, methanol, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.▲ (USP 1-May-2019) to: Acetonitrile and methanol (50:50… Read More |
TRYPSIN | CHEMICAL INFORMATION | Second Supplement to USP43–NF38 | Online | 20-Nov-2020 | 1-Dec-2020 | NA | NA | Change C1012H1555N279O324S14 23,293 (for bovine β-Trypsin) to: C1012H1585N279O324S14 23,293 (for bovine β-Trypsin) |
BUSPIRONE HYDROCHLORIDE | IDENTIFICATION/B. | USP42–NF37 | 618 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | Change relative retention time to: retention time |
AMITRIPTYLINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43 |
POLYETHYLENE GLYCOL | CHEMICAL INFORMATION | USP42–NF37 | 5882 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction |
DOXAZOSIN MESYLATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In USP Doxazosin Related Compound D RS: Change 1,4-Benzodioxane-2-carboxylic acid. C9H8O5 196.16 to: 1,4-Benzodioxane-2-carboxylic acid. C9H8O4 180.16 |
METOPROLOL SUCCINATE | USP Reference standards <11> | USP43–NF38 | 2917 | 29-May-2020 | 1-Jun-2020 | NA | NA | In USP Metoprolol Related Compound C RS: Change (±)4-[2-Hydroxy-3-(1-methylethyl)aminopropoxy]benzaldehyde. C13H19NO3 237.29 to: 4-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde hydrochloride. C13… Read More |
MUPIROCIN NASAL OINTMENT | Related compounds/Table 1 | USPNF Online | Online | 29-Apr-2022 | 1-May-2022 | NA | NA | In footnote 2: Change 9-{(E)-4-[(2R,3aS,6S,7S,8aRS)-2-{(1RS,2S,3S)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to:… Read More |
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS | ADDITIONAL REQUIREMENTS/Labeling | USP43–NF38 | 5378 | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In footnote 1: Change 1 mg of -alpha tocopheryl acetate to: 1 mg of all-rac-alpha tocopheryl acetate |
N-Benzoyl-L-arginine Ethyl Ester Hydrochloride | REAGENT SPECIFICATIONS | USPNF Online | Online | 30-Sep-2022 | 1-Dec-2022 | NA | NA | Change Crystallized Trypsin (USP Monograph). to: Trypsin (USP Monograph). |
GLYCYL-L-TYROSINE | IMPURITIES/Related Compounds | USPNF Online | Online | 24-Feb-2023 | 1-Jun-2023 | NA | NA | In Buffer solution: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water. |
UREA C 13 | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Isotopic Purity/Chromatographic system: Change Flow rate: Flow rate to: Flow rate: 1 mL/min |
METHYLNALTREXONE BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | Correct the chemical structure |
APREPITANT CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | Change Test 1 Dilute 1 mL of phosphoric acid with water to 1 L. to: Test 1 AND Change Dilute phosphoric acid: to: Dilute phosphoric acid: Dilute 1 mL of phosphoric acid with water to 1 L. |
GELATIN | SPECIFIC TESTS/Sulfur Dioxide | Harmonization (Official May 01, 2020) | 5783 | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In three instances in Analysis: Change 0.1 M sodium hydroxide to: Titrant AND In the equation: Change M to: N AND In the variable definition list: Change M = actual molarity of the … Read More |
DOXORUBICIN HYDROCHLORIDE FOR INJECTION | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
CALCIUM LACTATE | CHEMICAL INFORMATION | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | Change Calcium lactate (1:2) hydrate to: Calcium lactate hydrate AND Change Calcium lactate (1:2) pentahydrate to: Calcium lactate pentahydrate |
FOSAMPRENAVIR CALCIUM TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Dissolution 〈711〉/Medium: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows.… Read More |
FLUDROCORTISONE ACETATE TABLETS | IMPURITIES/Organic Impurities/Table 1 | Second Supplement to USP41–NF36 | 8843 | 22-Feb-2019 | 1-Mar-2019 | NA | NA | In footnote a: Change 9-Fluoro-11β,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate. to: 9-Fluoro-11β,17,21-trihydroxypregn-4-ene-3,20-dione. |
LIQUID GLUCOSE | ASSAY/Reducing Sugars | USP42–NF37 | 5741 | 31-May-2019 | 1-Jun-2019 | NA | NA | In the variable definition list in Analysis: Change CU = concentration of dextrose equivalent to: CU = concentration of Liquid Glucose |
GLYBURIDE AND METFORMIN HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 2128 | 26-Mar-2021 | 1-Apr-2021 | NA | NA | In USP Glyburide Related Compound A RS: Change 368.84 to: 368.83 |
<55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS | D-VALUE DETERMINATION | USP42–NF37 | 6385 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the third paragraph in Procedure: Change stated spore filter to: stated spore titer |
〈643〉 TOTAL ORGANIC CARBON | PROCEDURES | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In 1. Bulk Water/1.10 System suitability: Change rE = 100 × [(rC/rL) to: rE = 100 × (rC/rL) |
OIL-SOLUBLE VITAMINS TABLETS | STRENGTH | USP43–NF38 | 5356 | 24-Apr-2020 | 1-May-2020 | NA | NA | In Vitamin E, Method 3/Analysis: Change alpha -ocopheryl acetate to: alpha-tocopheryl acetate |
PROPYLENE GLYCOL DIACETATE | IMPURITIES/Organic Impurities | USPNF Online | Online | 25-Feb-2022 | 1-Mar-2022 | NA | NA | In Analysis: Change rS = sum of all the peak areas, excluding the solvent peaks from the Standard solution to: rS = sum of all the peak areas, excluding the solvent peaks from the Sample solution… Read More |
CARTEOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION | Assay | USP43–NF38 | 789 | 28-Aug-2020 | 1-Sep-2020 | NA | NA | Change pH 6.0 buffer, Mobile phase, Diluent, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Carteolol Hydrochloride. to: … Read More |
<871> SUTURES--NEEDLE ATTACHMENT | PROCEDURE | USPNF Online | Online | 29-Jul-2022 | 1-Aug-2022 | NA | NA | In Removable Needle Attachment: Change For USP sizes 5-0 through 2-0, to: For USP sizes 5-0 through 2, |
MESO-ZEAXANTHIN | COMPOSITION/Stereoisomeric Composition | USPNF Online | Online | 27-Jan-2023 | 1-Jun-2023 | NA | NA | In System suitability: Change [Note—The approximate relative retention times for (3S,3′S)-zeaxanthin, (3R,3′S-meso)-zeaxanthin, (3R,3′R)-zeaxanthin, and (3R,3′R,6′R)-lutein are 0.94… Read More |
ATORVASTATIN CALCIUM TABLETS | ASSAY/Procedure | USPNF Online | Online | 30-Jun-2023 | 1-Jul-2023 | NA | NA | In Analysis: Change Mr1 = molecular weight of atorvastatin, 558.64 Mr2 = molecular weight of atorvastatin calcium, 1155.34 to: Mr1 = molecular weight of atorvastatin, 558.65 M… Read More |
OLMESARTAN MEDOXOMIL TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Dissolution 〈711〉/Test 5/Apparatus 2: Change 50 rpm. Use peak vessels. to: 50 rpm. Use apex vessels. |
REAGENTS AND REFERENCE TABLES | REAGENT SPECIFICATIONS | USP42–NF37 | 6104 | 26-Apr-2019 | 1-May-2019 | NA | NA | In Ferric Nitrate: Change [10421-48-4]. to: [7782-61-8]. |
ATORVASTATIN CALCIUM | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 414 | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In USP Atorvastatin Related Compound C RS: Change Difluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3R,5R… Read More |
OXALIPLATIN INJECTION | IMPURITIES/Limit of Oxalic Acid/Chromatographic system | First Supplement to USP42–NF37 | 8781 | 26-Jul-2019 | 1-Aug-2019 | NA | NA | In Column: Change L31 to: L81 |
BIFIDOBACTERIUM LONGUM SUBSP. LONGUM | DEFINITION | USPNF 2021 ISSUE 1 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | Change Bifidobacteriumlongum subsp. longum comprises to: Bifidobacterium longum subsp. longum comprises |
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | 915 | 24-Apr-2020 | 1-May-2020 | NA | NA | In USP Cetirizine Related Compound A RS: Change 506.98 to: 506.97 |
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS | Dissolution <711> | USPNF 2021 ISSUE 1 | Online | 19-Nov-2021 | 1-Dec-2021 | NA | NA | In Test 2: Change Determine the amount of isosorbide dinitrate (C6H9NO6) dissolved by employing the following method. to: Determine the amount of isosorbide dinitrate (C6H8N2O… Read More |
TETRACAINE HYDROCHLORIDE | IMPURITIES/Organic Impurities | USP43–NF38 | 4295 | 29-May-2020 | 1-Jun-2020 | NA | NA | In Table 2: Change Tetracaine hydrochloride related compound B 1.7 0.4 Tetracaine hydrochloride related compound C 2.1 0.4 to: Tetracaine related compound B 1.7 0.4 Tetracaine related compound C 2.1 0.4 |
BENZETHONIUM CHLORIDE | IMPURITIES/Organic Impurities/Acceptance criteria | First Supplement to USP41–NF36 | 8297 | 25-Jan-2019 | 1-Feb-2019 | NA | NA | In Total impurities: Change 1.0% to: NMT 1.0% |
DIDANOSINE | IMPURITIES/Related Compounds | USP42–NF37 | 1336 | 31-May-2019 | 1-Jun-2019 | NA | NA | In System suitability solution: Change 0.5 mg/mL of of didanosine from USP Didanosine System Suitability Mixture RS in Diluent to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in Diluent |